MicroRNAs (miRNAs) are evolutionarily conserved small non-coding RNAs, which regulate gene expression in a sequence-specific manner. The potential regulatory circuitry afforded by miRNA is enormous. Rapidly accumulating evidence indicates that miRNAs play critical roles in cancer. Our earlier findings that miRNAs exhibit genomic alterations at high frequency and their expression is remarkably deregulated in ovarian and breast cancers, strongly suggest that miRNAs are involved in the initiation and progression of cancer. Therefore, investigation of miRNA function in cancer will provide novel strategies for both diagnosis and treatment of cancer patients. Our preliminary studies have identified mir-30d as a potential oncogene. First, mir-30d plays a critical role in both epithelial transformation and established epithelial tumor growth. Second, mir-30d may directly regulate certain cancer-associated pathways. Third, the DNA copy number of mir-30d is frequently amplified in multiple types of human epithelial tumors. Meanwhile, overexpression of mir-30d is significantly associated with poor clinical outcome in ovarian cancer patients. Forth, pre-mir-30d is induced by hypoxia and prevents tumor cells from apoptosis. Finally, mir-30d inhibitor treatment is capable to remarkably reduce tumor cell growth. We hypothesize that mir-30d plays a critical role in breast and ovarian epithelial malignant transformation and tumor development.
Specific Aim 1 : Define the molecular mechanism of mir-30d in preventing hypoxia-induced apoptosis. We will dissect the transcriptional regulation of mir-30d under hypoxia and map the prosurvival pathways downstream of mir-30d.
Specific Aim 2 : Examine the function of mir-30d in preventing hypoxia-induced apoptosis in vivo. We will examine the function of mir-30d in vivo in a novel tetracycline-inducible human tumor xenograft model and a large collection of human ovarian and breast tumor specimens.
Specific Aim 3 : Investigate the role of mir-30d in tumorigenesis. We will examine the early transformation ability induced by mir-30d activation in vivo. After having completed the proposed studies, we will be able to test mir-30d targeted therapy using mir-30d ASO in pre-clinical animal models. If successful, our long-term goal is to commence phase I/II clinical trials in ovarian cancer patients using mir-30d ASO.

Public Health Relevance

Ovarian and breast cancers are the most important causes of cancer-related mortality in women. microRNAs are small non-coding RNAs, which regulate gene expression in a sequence-specific manner. We will conduct a detailed study of mir-30d in ovarian and breast cancer with the intent to (i) learn important lessons in ovarian and breast cancer biology;(ii) discover novel therapeutic target.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA142776-05
Application #
8591382
Study Section
Molecular Oncogenesis Study Section (MONC)
Program Officer
Mietz, Judy
Project Start
2010-03-01
Project End
2014-12-31
Budget Start
2014-01-01
Budget End
2014-12-31
Support Year
5
Fiscal Year
2014
Total Cost
$289,837
Indirect Cost
$108,689
Name
University of Pennsylvania
Department
Obstetrics & Gynecology
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Zhong, Qian; Peng, Hong-Ling; Zhao, Xia et al. (2015) Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis. Clin Cancer Res 21:211-20
Hu, Xiaowen; Feng, Yi; Zhang, Dongmei et al. (2014) A functional genomic approach identifies FAL1 as an oncogenic long noncoding RNA that associates with BMI1 and represses p21 expression in cancer. Cancer Cell 26:344-57
Feng, Yi; Hu, Xiaowen; Zhang, Youyou et al. (2014) Methods for the study of long noncoding RNA in cancer cell signaling. Methods Mol Biol 1165:115-43
Hu, Xiaowen; Guo, Jinyi; Zheng, Lan et al. (2013) The heterochronic microRNA let-7 inhibits cell motility by regulating the genes in the actin cytoskeleton pathway in breast cancer. Mol Cancer Res 11:240-50
Yang, Xiaojun; Zhong, Xiaomin; Tanyi, Janos L et al. (2013) mir-30d Regulates multiple genes in the autophagy pathway and impairs autophagy process in human cancer cells. Biochem Biophys Res Commun 431:617-22
Li, Ning; Kaur, Sippy; Greshock, Joel et al. (2012) A combined array-based comparative genomic hybridization and functional library screening approach identifies mir-30d as an oncomir in cancer. Cancer Res 72:154-64
Zhong, Xiaomin; Coukos, George; Zhang, Lin (2012) miRNAs in human cancer. Methods Mol Biol 822:295-306
Li, Ning; Zhong, Xiaomin; Lin, Xiaojuan et al. (2012) Lin-28 homologue A (LIN28A) promotes cell cycle progression via regulation of cyclin-dependent kinase 2 (CDK2), cyclin D1 (CCND1), and cell division cycle 25 homolog A (CDC25A) expression in cancer. J Biol Chem 287:17386-97
Huang, Jia; Zhang, Lin; Greshock, Joel et al. (2011) Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome. Genes Chromosomes Cancer 50:606-18
Yang, Xiaojun; Lin, Xiaojuan; Zhong, Xiaomin et al. (2010) Double-negative feedback loop between reprogramming factor LIN28 and microRNA let-7 regulates aldehyde dehydrogenase 1-positive cancer stem cells. Cancer Res 70:9463-72

Showing the most recent 10 out of 11 publications